Do you want to read an article? Please log in or register.
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Skin Cancer
Related content
Skin Cancer
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
Eur J Cancer
Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, Stroyakovskiy D, Kozlov V, Zimina A, Mochalova A, Demidova S, Lyadova M, Kutkovich A, Skopin P, Kovalenko N, Safina S, Volkov V, Semiletova Y, Vaschenko V, Kislov N, Poltoratskiy A, Shumskaya I, Kolomiets S, Sobolev A, Belogortsev I, Odintsova S, Rastogi S, Andabekov T, Penkov K, Semenova A, Obukhov A, Belyakovsky V, Yurchenkov A, Gladkov O, Neve R, Falaleeva N, Poddubskaya E, Vaibhav A, Kirtbaya D, Chapko Y, Smagina M, Fadeeva N, Sorokina I, Mikhailova E, Linkova Y, Zinkina-Orikhan A, Lutskii A, Gabidullin R, Rzaev R, Kryukov F
doi: 10.1016/j.ejca.2025.115674
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548
Skin Cancer
Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system
Eur J Cancer
Samaran Q, Bettuzzi T, Sbidian E
doi: 10.1016/j.ejca.2026.116585
Lung, Respiratory and Thoracic Cancer
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Lung Cancer
Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C
doi: 10.1016/j.lungcan.2025.108583
Skin Cancer
Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study
Eur J Cancer
Pedersen S, Colmorn LB, Ellebaek E, Kristensen SG, Ruhlmann C, Borch TH, Donia M, Fedder J, Macklon KT, Svane IM
doi: 10.1016/j.ejca.2026.116584
Skin Cancer
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
Int J Cancer
Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D
doi: 10.1002/ijc.70440
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Lung, Respiratory and Thoracic Cancer
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Lancet Oncol
Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B
doi: 10.1016/S1470-2045(25)00429-2
Gastrointestinal Cancer
Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study
Eur J Cancer
Ghedri A, van der Baan FH, Otten JMMB, Elferink MAG, Terheggen F, Hendriks MP, May AM, Koopman M, Punt CJA, Kwakman JJM, PLCRC study group
doi: 10.1016/j.ejca.2026.116588